FR15C0072I1 - - Google Patents

Info

Publication number: FR15C0072I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2015-10-21

Publication date

2015-04-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0072(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-12 Publication of FR15C0072I1 publication Critical patent/FR15C0072I1/fr

2015-10-21 Application filed filed Critical

2019-05-17 Application granted granted Critical

2019-05-17 Publication of FR15C0072I2 publication Critical patent/FR15C0072I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

FR15C0072C 2003-09-03 2015-10-21 COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) Active FR15C0072I2 (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
EP04787096.9A EP1663240B2 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number	Publication Date
FR15C0072I1 true FR15C0072I1 (en)	2015-04-12
FR15C0072I2 FR15C0072I2 (en)	2019-05-17

Family

ID=34280181

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
FR15C0072C Active FR15C0072I2 (en)	2003-09-03	2015-10-21	COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
FR15C0071C Active FR15C0071I2 (en)	2003-09-03	2015-10-21	COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
FR15C0073C Active FR15C0073I2 (en)	2003-09-03	2015-10-21	COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
FR15C0071C Active FR15C0071I2 (en)	2003-09-03	2015-10-21	COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)
FR15C0073C Active FR15C0073I2 (en)	2003-09-03	2015-10-21	COMBINATION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING A PYRIMIDINE WITH A NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI)

Country Status (25)

Country	Link
US (9)	US20080200435A1 (en)
EP (1)	EP1663240B2 (en)
JP (3)	JP5507791B2 (en)
KR (1)	KR20060090658A (en)
CN (1)	CN101060844B (en)
AP (1)	AP2109A (en)
AU (5)	AU2004268390B2 (en)
BE (1)	BE2015C053I2 (en)
CA (1)	CA2537095C (en)
CY (5)	CY2015040I2 (en)
FI (1)	FI1663240T4 (en)
FR (3)	FR15C0072I2 (en)
HK (1)	HK1092698A1 (en)
HR (1)	HRP20150798T4 (en)
HU (5)	HUS1500054I1 (en)
IL (2)	IL173438A (en)
LT (2)	LTPA2016045I1 (en)
LU (3)	LU92853I2 (en)
MX (1)	MXPA06002437A (en)
MY (1)	MY169670A (en)
NL (2)	NL300781I1 (en)
NO (5)	NO334877B1 (en)
NZ (1)	NZ545306A (en)
PL (1)	PL1663240T5 (en)
WO (1)	WO2005021001A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (en)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	Hiv inhibiting pyrimidines derivatives
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JP4822707B2 (en)	2002-08-09	2011-11-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Process for producing 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
SI1583542T1 (en)	2003-01-14	2008-12-31	Gilead Sciences Inc	Compositions and methods for combination antiviral therapy
CA2577288C (en) *	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
SG155885A1 (en) *	2004-09-02	2009-10-29	Janssen Pharmaceutica Nv	Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
CA2577273C (en) *	2004-09-02	2013-11-19	Janssen Pharmaceutica N.V.	Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP4912309B2 (en) *	2004-09-02	2012-04-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Hydrochloride of 4-[[4-[[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
US20090215804A1 (en) *	2004-09-02	2009-08-27	Paul Theodoor Agnes Stevens	Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
TWI457136B (en) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Prevention of hiv-infection
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	Unitary pharmaceutical dosage form
ATE474560T1 (en) *	2005-12-14	2010-08-15	Cipla Ltd	PHARMACEUTICAL COMBINATION OF NUCLEOTIDE AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (SUCH AS TENOFOVIR AND LAMIVUDINE) IN DIFFERENT PARTS OF THE DOSAGE UNIT
SG170073A1 (en) *	2006-01-20	2011-04-29	Tibotec Pharm Ltd	Long term treatment of hiv infection
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (en)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT
TWI494133B (en) *	2007-03-14	2015-08-01	Tibotec Pharm Ltd	Powders for reconstitution
CA2711569C (en) *	2008-01-03	2017-08-01	Universite De La Mediterannee, Aix-Marseille Ii	Composition and processes for use in an anti-hiv treatment
SG196774A1 (en) *	2008-12-24	2014-02-13	Tibotec Pharm Ltd	Implantable devices for treating hiv
MY163383A (en)	2009-12-21	2017-09-15	Janssen Sciences Ireland Uc	Degradable removable implant for the sustained release of an active compound
MX356891B (en)	2010-01-27	2018-06-19	Viiv Healthcare Co	Antiviral therapy.
UA114075C2 (en)	2010-11-19	2017-04-25		MULTI-LAYER TABLE CONTAINING RILPIVIRINE HCl, EMTRICITABIN AND TENOFOVIR DISOPROXYLFUMARATE
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) *	2011-09-16	2018-05-16	Hetero Research Foundation	Rilpivirine hydrochloride
CN111303152B (en)	2012-12-21	2023-04-11	吉利德科学公司	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3346995B1 (en)	2015-11-09	2019-08-28	Gilead Sciences, Inc.	Therapeutic compositions for treatment of human immunodeficiency virus
SI3528791T1 (en)	2016-10-24	2024-04-30	Janssen Sciences Ireland Unlimited Company	Dispersible compositions
US20210128554A1 (en) *	2016-12-23	2021-05-06	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
EP3612226A1 (en) *	2017-04-18	2020-02-26	Cipla Limited	Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) *	2017-07-27	2019-01-31	Cipla Limited	Pharmaceutical compositions
KR20220109389A (en)	2019-11-29	2022-08-04	스키피오 라이프 사이언스 리미티드	Compositions comprising rilpivirine and use thereof for the treatment of tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
US5316773A (en)	1990-07-19	1994-05-31	Otsuka Pharmaceutical Co., Ltd.	Particulate preparation containing a flourracil derivative and hydroxypropylmethyl-cellulose
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5837747A (en) *	1991-10-29	1998-11-17	Vivorx, Inc.	Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU4079593A (en)	1992-05-13	1993-12-13	Wellcome Foundation Limited, The	Therapeutic combinations
JPH06316524A (en)	1992-09-11	1994-11-15	Naoyuki Inoue	Anti-aids virus agent
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (en) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN COMBINATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
DE60020382T2 (en)	1999-09-21	2006-01-26	Skyepharma Canada Inc., Verdun	SURFACE-MODIFIED PARTICULATE COMPOSITIONS OF BIOLOGICALLY ACTIVE SUBSTANCES
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) *	2000-01-27	2008-01-01	Zentaris Ag	Compressed microparticles for dry injection
EP1267879A2 (en)	2000-03-30	2003-01-02	Bristol-Myers Squibb Company	Sustained release beadlets containing stavudine
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (en)	2000-10-11	2002-04-25	Ethicon Gmbh	Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation
CA2431319A1 (en)	2000-12-11	2002-06-20	Hiroto Bando	Pharmaceutical composition having an improved water solubility
PT1404300E (en)	2001-06-22	2009-11-09	Bend Res Inc	Pharmaceutical compositions of dispersions of drugs and neutral polymers
JO3429B1 (en) †	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	Hiv inhibiting pyrimidines derivatives
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002364701B8 (en)	2001-11-20	2006-06-22	Alkermes, Inc.	Compositions for sustained action product delivery
JP4822707B2 (en)	2002-08-09	2011-11-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Process for producing 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
WO2004022033A1 (en) *	2002-09-04	2004-03-18	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en)	2002-11-08	2004-06-03	Glaxo Group Limited	Pharmaceutical antiviral compositions
JP2006508145A (en)	2002-11-15	2006-03-09	テイボテク・フアーマシユーチカルズ・リミテツド	Substituted indole pyridinium as an anti-infective compound
WO2004050068A1 (en)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AP2065A (en)	2003-02-07	2009-11-26	Janssen Pharmaceutica Nv	Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (en) *	2004-01-27	2006-09-28	씨제이 주식회사	Process for preparing oltipraz with diminished crystalline state or amorphous state
JP2008501802A (en)	2004-06-08	2008-01-24	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Pharmaceutical composition
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en)	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JP4912309B2 (en)	2004-09-02	2012-04-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Hydrochloride of 4-[[4-[[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
EP2623095A1 (en)	2004-11-16	2013-08-07	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
TWI457136B (en)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Prevention of hiv-infection
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060269475A1 (en) *	2005-04-11	2006-11-30	Ryu Wonhyoung	Multi-layer structure having a predetermined layer pattern including an agent
EP1893180A2 (en)	2005-06-07	2008-03-05	Pfizer Products Inc.	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1909762A2 (en)	2005-07-28	2008-04-16	Isp Investments Inc.	Amorphous efavirenz and the production thereof
SG170073A1 (en)	2006-01-20	2011-04-29	Tibotec Pharm Ltd	Long term treatment of hiv infection
US20090176813A1 (en)	2006-06-23	2009-07-09	Lieven Elvire Colette Baert	Aqueous suspensions of tmc278
WO2008060360A2 (en) *	2006-09-28	2008-05-22	Surmodics, Inc.	Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (en)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	Powders for reconstitution
AU2008274185B2 (en)	2007-07-12	2014-07-03	Janssen Sciences Ireland Uc	Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
WO2009046299A2 (en)	2007-10-04	2009-04-09	Boston Scientific Scimed, Inc	Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) *	2008-10-24	2011-10-20	Harbeson Scott L	Hydroxyethlamino Sulfonamide Derivatives

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en active Application Filing
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/en active IP Right Grant
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/en active Active
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en active Active
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/en active Search and Examination
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/en active Active
- 2004-09-03 CA CA2537095A patent/CA2537095C/en active Active
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/en unknown
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en active Active
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/en active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/en active IP Right Maintenance
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en active Active
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/en not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/en active Active
- 2014-12-18 NO NO2014030C patent/NO2014030I1/en unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/en not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/en unknown
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/en unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/en unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/en active Active
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/en unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I2/en unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/en active Active
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/en unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/en unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/en unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/en active Active
- 2015-10-21 LU LU92855C patent/LU92855I2/en unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I2/en unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/en unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/en unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/en unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/en active
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/en unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/en unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I1/en unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/en unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I1/en unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NL300768I1 (en)	2015-12-16
LU92853I2 (en)	2015-12-21
EP1663240B2 (en)	2023-03-01
LTC1663240I2 (en)	2022-05-25
US20170100398A1 (en)	2017-04-13
LTPA2016045I1 (en)	2017-01-10
JP2015044839A (en)	2015-03-12
KR20060090658A (en)	2006-08-14
HK1092698A1 (en)	2007-02-16
EP1663240A1 (en)	2006-06-07
US20150283135A1 (en)	2015-10-08
MY169670A (en)	2019-05-08
AU2011201123B2 (en)	2013-10-10
IL173438A (en)	2012-03-29
AU2004268390B2 (en)	2011-03-31
IL213104A0 (en)	2011-07-31
HUS1600058I1 (en)	2017-02-28
CY2015038I1 (en)	2016-08-31
PL1663240T3 (en)	2015-10-30
HRP20150798T1 (en)	2015-09-11
CY2016049I2 (en)	2017-07-12
NO2014031I1 (en)	2015-01-05
IL213104A (en)	2016-02-29
FR15C0071I2 (en)	2016-02-12
MXPA06002437A (en)	2006-06-20
FR15C0072I2 (en)	2019-05-17
NO2016025I1 (en)	2016-12-20
CA2537095C (en)	2012-05-29
EP1663240B1 (en)	2015-04-22
AU2004268390A1 (en)	2005-03-10
CY2015040I1 (en)	2016-08-31
CY2016049I1 (en)	2017-07-12
US20100029591A1 (en)	2010-02-04
AP2109A (en)	2010-02-26
HRP20150798T4 (en)	2023-06-09
NO2014030I2 (en)	2014-12-18
AU2014203484B2 (en)	2016-09-29
AU2019200813A1 (en)	2019-02-28
NL300781I2 (en)	2016-04-19
US20080200435A1 (en)	2008-08-21
NO20061374L (en)	2006-03-27
CY2016048I2 (en)	2017-07-12
HUS1500054I1 (en)	2016-03-29
FR15C0073I2 (en)	2016-02-12
IL173438A0 (en)	2006-06-11
NO2014031I2 (en)	2014-12-18
FI1663240T4 (en)	2023-04-25
AU2014203484A1 (en)	2014-07-17
AP2006003551A0 (en)	2006-04-30
BE2015C053I2 (en)	2023-12-14
FR15C0073I1 (en)	2015-04-12
WO2005021001A1 (en)	2005-03-10
US20140349971A1 (en)	2014-11-27
LU92854I2 (en)	2015-12-21
AU2016210733B2 (en)	2018-11-08
CN101060844A (en)	2007-10-24
US20220008417A1 (en)	2022-01-13
NL300768I2 (en)	2023-08-09
US20200171027A1 (en)	2020-06-04
CY2015040I2 (en)	2016-08-31
LTPA2016044I1 (en)	2017-01-10
FR15C0071I1 (en)	2015-04-12
US20180228800A1 (en)	2018-08-16
NO2014030I1 (en)	2015-01-05
CN101060844B (en)	2012-01-04
NO2014032I1 (en)	2015-01-05
NO2014032I2 (en)	2014-12-18
NL300781I1 (en)	2016-04-19
CA2537095A1 (en)	2005-03-10
US8841310B2 (en)	2014-09-23
JP2007520443A (en)	2007-07-26
JP2012051915A (en)	2012-03-15
CY2015038I2 (en)	2016-08-31
PL1663240T5 (en)	2024-02-26
AU2016210733A1 (en)	2016-08-25
HUS1500052I1 (en)	2016-03-29
HUS1500053I1 (en)	2016-03-29
AU2011201123A1 (en)	2011-04-07
NZ545306A (en)	2009-11-27
JP5507791B2 (en)	2014-05-28
CY2015039I1 (en)	2016-08-31
US20190216807A1 (en)	2019-07-18
HUS1600059I1 (en)	2017-02-28
CY2015039I2 (en)	2016-08-31
LU92855I2 (en)	2015-12-21
CY2016048I1 (en)	2017-07-12
JP5820045B2 (en)	2015-11-24
NO334877B1 (en)	2014-06-23

Publication	Publication Date	Title
NL300768I1 (en)	2015-12-16
BE2015C007I2 (en)	2023-08-09
BE2014C055I2 (en)	2023-12-14
BE2014C027I2 (en)	2023-12-14
BE2014C003I2 (en)	2023-08-09
BE2013C075I2 (en)	2023-12-18
BE2013C070I2 (en)	2023-12-18
BE2013C067I2 (en)	2023-08-09
FR13C0035I1 (en)	2013-08-09
BE2013C036I2 (en)	2023-12-14
BE2011C030I2 (en)	2023-03-07
JP2004056784A5 (en)	2006-07-27
JP2004096065A5 (en)	2006-03-16
JP2004204846A5 (en)	2007-02-08
IN2006DE01990A (en)	2007-07-13
IN2006CH00292A (en)	2007-07-06
JP2004228466A5 (en)	2006-03-02
BE2015C005I2 (en)	2023-03-07
IN246332B (en)	2011-03-04
BE2012C053I2 (en)	2023-08-09
JP2004177919A5 (en)	2006-03-30
JP2004222173A5 (en)	2006-03-02
JP2004214458A5 (en)	2005-09-08
JP2004006254A5 (en)	2006-04-13
JP2004045396A5 (en)	2006-06-29